Emerging investigations on retatrutides, a dual stimulant for GLP-1 and glucose-dependent insulinotropic polypeptide, demonstrate promising outcomes in treating excess body fat and type 2 diabetes. Initial information from clinical experiments show considerable reductions in body bulk and improve